GHDX stock forecast
Our latest prediction for Genomic Health, Inc.'s stock price was made on the Oct. 8, 2019 when the stock price was at 67.56$.
In the short term (2weeks), GHDX's stock price should outperform the market by 1.19%. During that period the price should oscillate between -4.84% and +6.21%.
In the medium term (3months), GHDX's stock price should outperform the market by 5.18%. During that period the price should oscillate between -11.80% and +18.40%.Get email alerts
Create a solid portfolio with GHDX
About Genomic Health, Inc.
Genomic Health, Inc. engages in the provision of genomic-based diagnostic tests. Its tests analyze the underlying biology of cancers, allowing physicians and patients to make individualized treatment decisions. The firm uses a platform which translates a massive amount of clinical and genomic data into clinically actionable results for treatment planning. Genomic Health was founded by Patrick F. Terry, Joffre B. Baker, Randal W. Scott, and Steven Shak in August 2000 and is headquartered in Redwood City, CA.
At the moment the company generates 429M USD in revenues.
On its last earning announcement, the company reported a profit of 1.31$ per share.
The book value per share is 6.28$
Three months stock forecastOct. 8, 2019
|Revenue USD||Gross Margin||Operating Income||Operating Margin||Net Income||Earnings Per Share||Dividends||Payout Ratio||Shares||Book Value Per Share||Operating Cash Flow||Cap Spending||Free Cash Flow|